← All Therapeuticsmd, INC filings

Therapeuticsmd, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TXMD
Therapeuticsmd, INC
10-K/A: TherapeuticsMD Faces Going Concern Amid Legal Battles
TherapeuticsMD, a pharmaceutical royalty company, reported reduced net losses in 2025 but faces substantial doubt about its ability to continue as a going concern due to ongoing legal disputes and liquidity challenges.
NASDAQ
TXMD
Therapeuticsmd, INC
10-K: TherapeuticsMD Navigates Royalty Model Amid Legal Battles
TherapeuticsMD reports reduced net loss and increased license revenue in 2025, but faces substantial doubt about its going concern status due to ongoing legal disputes and liquidity challenges.
NASDAQ
TXMD
Therapeuticsmd, INC
10-K/A: TherapeuticsMD Files Amended 10-K to Include Omitted Information on Directors, Executive Pay, and Governance
TherapeuticsMD files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.
NASDAQ
TXMD
Therapeuticsmd, INC
10-K: TherapeuticsMD Reports 2024 Results, Navigates Going Concern Uncertainty
TherapeuticsMD, now a royalty-focused company, faces going concern doubts despite revenue increase and cost reductions following its strategic shift in 2022.
NASDAQ
TXMD
Therapeuticsmd, INC
10-K/A: TherapeuticsMD Files Amended 10-K to Include Omitted Information
TherapeuticsMD files an amendment to its annual report to include information previously omitted regarding directors, executive compensation, and related matters.
NASDAQ
TXMD
Therapeuticsmd, INC
10-K: TherapeuticsMD Transforms into Royalty Company, Reports Full Year 2023 Results
TherapeuticsMD transitioned to a pharmaceutical royalty company in 2022, licensing its products and reporting a net loss of $10.3 million for 2023.